MetaCap

BioVie (BIVI) vs Vyome (HIND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie (BIVI) has outperformed Vyome (HIND) over the past year, losing 38.2% versus a loss of 75.9%. Over five years, BIVI leads with a -99.9% price change compared with -100.0% for HIND. BioVie is the larger company by market cap ($8.6 million vs $8.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIVI-38.22%HIND-75.90%
+84%+0%-84%
Nov 21, 20251 yearNov 20, 2026
BIVI-99.86%HIND-100.00%
+138%+13%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIVI versus HIND key metrics
MetricBIVIHIND
Share price$0.80$1.20
Market cap$8.58M$8.42M
1-day change-12.07%-17.24%
YTD return-31.03%-65.12%
1-year return-38.22%-75.90%
5-year return-99.87%-100.00%
P/E ratio (TTM)—0.25
EPS (TTM)$-2.85$4.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$319.71K
Revenue growth (YoY)—+24.43%
Net income (latest FY)$-22.07M$-10.26M
Gross margin—68.43%
Operating margin—-3269.35%
Net margin—-3209.75%
52-week high$3.79$5.88
52-week low$0.7515$1.20
Distance from 52-week high-78.89%-79.59%
Analyst consensusnonestrong_buy
Avg. price target upside+557.50%+635.83%
Average volume568.61K13.92K
Shares outstanding10.72M7.02M
Employees139
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BIVI has outperformed HIND by 37.7 percentage points over the past year.

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Vyome

HIND stock →

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

BIVI vs HIND FAQ

Which is bigger, BioVie or Vyome?

BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.42M for Vyome (HIND).

Which stock has performed better over the past year, BIVI or HIND?

BIVI returned -38.22% over the past 12 months, compared with -75.90% for HIND (price return, excluding dividends). Past performance does not predict future results.

Are BioVie and Vyome in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons